Do analysts recommend ZVSA or APVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aptevo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, ZVSA or APVO?

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZyVersa Therapeutics N/A N/A -$9.41M -$0.83 N/A Aptevo Therapeutics N/A N/A -$25.97M -$51.83 N/A

Is ZVSA or APVO more profitable?

ZyVersa Therapeutics' return on equity of -109.54% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ZyVersa Therapeutics N/A -109.54% -43.95% Aptevo Therapeutics N/A -201.49% -119.21%

Do analysts prefer GOVX or ZVSA?

GeoVax Labs presently has a consensus price target of $150.00, indicating a potential upside of 42,635.04%. Given GeoVax Labs' stronger consensus rating and higher possible upside, equities research analysts plainly believe GeoVax Labs is more favorable than ZyVersa Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, GOVX or ZVSA?

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeoVax Labs N/A N/A -$21.47M -$11.34 N/A ZyVersa Therapeutics N/A N/A -$9.41M -$0.83 N/A

Is GOVX or ZVSA more profitable?

ZyVersa Therapeutics' return on equity of -109.54% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% ZyVersa Therapeutics N/A -109.54% -43.95%

Do analysts recommend ONCO or ZVSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer GNPX or ZVSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, GNPX or ZVSA?

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genprex N/A N/A -$16.23M -$133.36 N/A ZyVersa Therapeutics N/A N/A -$9.41M -$0.83 N/A

Is GNPX or ZVSA more profitable?

ZyVersa Therapeutics' return on equity of -109.54% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -163.12% -128.98% ZyVersa Therapeutics N/A -109.54% -43.95%

Do analysts recommend ZVSA or BTAI?

BioXcel Therapeutics has a consensus price target of $11.00, indicating a potential upside of 14,744.80%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than ZyVersa Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

ZyVersa Therapeutics (ZVSA) Competitors

$0.10 0.00 (0.00%)

As of 09/25/2026

Compare

ZVSA vs. APVO, GOVX, ONCO, GNPX, and BTAI

Should you buy ZyVersa Therapeutics stock or one of its competitors? ZyVersa Therapeutics's main competitors and comparable companies include Aptevo Therapeutics (APVO), GeoVax Labs (GOVX), Onconetix (ONCO), Genprex (GNPX), and BioXcel Therapeutics (BTAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ZyVersa Therapeutics compare to Aptevo Therapeutics?

ZyVersa Therapeutics (NASDAQ:ZVSA) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

In the previous week, Aptevo Therapeutics had 2 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 2 mentions for Aptevo Therapeutics and 0 mentions for ZyVersa Therapeutics. Aptevo Therapeutics' average media sentiment score of 0.27 beat ZyVersa Therapeutics' score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ZyVersa Therapeutics	Neutral
Aptevo Therapeutics	Neutral

ZyVersa Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$51.83	N/A

ZyVersa Therapeutics' return on equity of -109.54% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-109.54%	-43.95%
Aptevo Therapeutics	N/A	-201.49%	-119.21%

3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Comparatively, 0.4% of Aptevo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aptevo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Aptevo Therapeutics beats ZyVersa Therapeutics on 7 of the 11 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to GeoVax Labs?

GeoVax Labs (NASDAQ:GOVX) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

ZyVersa Therapeutics' return on equity of -109.54% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

GeoVax Labs has a beta of 3.66, suggesting that its stock price is 266% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

GeoVax Labs presently has a consensus price target of $150.00, indicating a potential upside of 42,635.04%. Given GeoVax Labs' stronger consensus rating and higher possible upside, equities research analysts plainly believe GeoVax Labs is more favorable than ZyVersa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	N/A	N/A	-$21.47M	-$11.34	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

In the previous week, GeoVax Labs had 2 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for ZyVersa Therapeutics. GeoVax Labs' average media sentiment score of 0.91 beat ZyVersa Therapeutics' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Overall Sentiment
GeoVax Labs	Positive
ZyVersa Therapeutics	Neutral

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 0.2% of GeoVax Labs shares are owned by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

GeoVax Labs beats ZyVersa Therapeutics on 9 of the 13 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Onconetix?

Onconetix (NASDAQ:ONCO) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ZyVersa Therapeutics has lower revenue, but higher earnings than Onconetix. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	5.57	-$14.03M	$248.12	0.00
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

In the previous week, Onconetix had 7 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 7 mentions for Onconetix and 0 mentions for ZyVersa Therapeutics. Onconetix's average media sentiment score of 0.26 beat ZyVersa Therapeutics' score of 0.00 indicating that Onconetix is being referred to more favorably in the media.

Company	Overall Sentiment
Onconetix	Neutral
ZyVersa Therapeutics	Neutral

23.9% of Onconetix shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 0.3% of Onconetix shares are owned by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Onconetix has a beta of 2.68, suggesting that its share price is 168% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

ZyVersa Therapeutics has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat ZyVersa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,575.89%	-91.95%	-53.76%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

Summary

Onconetix beats ZyVersa Therapeutics on 10 of the 13 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Genprex?

Genprex (NASDAQ:GNPX) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Genprex has a beta of -0.94, indicating that its stock price is 194% less volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

ZyVersa Therapeutics' return on equity of -109.54% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-163.12%	-128.98%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

14.1% of Genprex shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 0.3% of Genprex shares are owned by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Genprex had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 1 mentions for Genprex and 0 mentions for ZyVersa Therapeutics. Genprex's average media sentiment score of 1.82 beat ZyVersa Therapeutics' score of 0.00 indicating that Genprex is being referred to more favorably in the media.

Company	Overall Sentiment
Genprex	Very Positive
ZyVersa Therapeutics	Neutral

Summary

Genprex beats ZyVersa Therapeutics on 6 of the 11 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to BioXcel Therapeutics?

ZyVersa Therapeutics (NASDAQ:ZVSA) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

ZyVersa Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

ZyVersa Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -9,549.87%. BioXcel Therapeutics' return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-109.54%	-43.95%
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%

BioXcel Therapeutics has a consensus price target of $11.00, indicating a potential upside of 14,744.80%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than ZyVersa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

ZyVersa Therapeutics has higher earnings, but lower revenue than BioXcel Therapeutics. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A
BioXcel Therapeutics	$640K	3.63	-$69.90M	-$3.79	N/A

3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, BioXcel Therapeutics had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 1 mentions for BioXcel Therapeutics and 0 mentions for ZyVersa Therapeutics. ZyVersa Therapeutics' average media sentiment score of 0.00 equaled BioXcel Therapeutics'average media sentiment score.

Company	Overall Sentiment
ZyVersa Therapeutics	Neutral
BioXcel Therapeutics	Neutral

Summary

BioXcel Therapeutics beats ZyVersa Therapeutics on 9 of the 14 factors compared between the two stocks.

Get ZyVersa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZVSA vs. The Competition

Export

Metric	ZyVersa Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$786K	$3.94B	$7.33B	$13.17B
Dividend Yield	N/A	3.63%	2.52%	14.03%
P/E Ratio	-0.12	14.15	275.82	25.78
Price / Sales	N/A	1,438.70	649.60	92.85
Price / Cash	N/A	120.91	79.52	52.89
Price / Book	0.03	15.28	10.44	6.30
Net Income	-$9.41M	-$22.90M	$3.51B	$360.35M
7 Day Performance	N/A	-2.94%	-1.31%	-0.23%
1 Month Performance	N/A	-8.80%	-4.61%	-4.16%
1 Year Performance	N/A	28.99%	15.01%	4.58%

ZyVersa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZVSA ZyVersa Therapeutics	N/A	$0.10 flat	N/A	-33.0%	$786K	N/A	N/A	2
APVO Aptevo Therapeutics	0.4406 of 5 stars	$1.84 +7.0%	N/A	-93.0%	$3.11M	N/A	N/A	50	News Coverage Positive News Analyst Downgrade Short Interest Increase Gap Up High Trading Volume
GOVX GeoVax Labs	2.5224 of 5 stars	$0.38 -5.5%	$150.00 +39,064.5%	-97.8%	$2.99M	N/A	N/A	10
ONCO Onconetix	1.6167 of 5 stars	$0.66 +0.0%	N/A	-99.4%	$2.91M	$810K	0.00	12	News Coverage Analyst Upgrade
GNPX Genprex	0.7201 of 5 stars	$3.46 +1.5%	N/A	-98.3%	$2.80M	N/A	N/A	20	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZVSA) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ZyVersa Therapeutics (ZVSA) Competitors

ZVSA vs. APVO, GOVX, ONCO, GNPX, and BTAI

How does ZyVersa Therapeutics compare to Aptevo Therapeutics?

Summary

How does ZyVersa Therapeutics compare to GeoVax Labs?

Summary

How does ZyVersa Therapeutics compare to Onconetix?

Summary

How does ZyVersa Therapeutics compare to Genprex?

Summary

How does ZyVersa Therapeutics compare to BioXcel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVSA vs. The Competition

ZyVersa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ZyVersa Therapeutics (ZVSA) Competitors

ZVSA vs. APVO, GOVX, ONCO, GNPX, and BTAI

How does ZyVersa Therapeutics compare to Aptevo Therapeutics?

Does the media favor ZVSA or APVO?

Which has more risk and volatility, ZVSA or APVO?

Which has stronger earnings and valuation, ZVSA or APVO?

Is ZVSA or APVO more profitable?

Do institutionals and insiders believe in ZVSA or APVO?

Do analysts recommend ZVSA or APVO?

Summary

How does ZyVersa Therapeutics compare to GeoVax Labs?

Is GOVX or ZVSA more profitable?

Which has more risk and volatility, GOVX or ZVSA?

Do analysts prefer GOVX or ZVSA?

Which has preferable earnings & valuation, GOVX or ZVSA?

Does the media refer more to GOVX or ZVSA?

Do insiders & institutionals hold more shares of GOVX or ZVSA?

Summary

How does ZyVersa Therapeutics compare to Onconetix?

Do analysts recommend ONCO or ZVSA?

Which has higher earnings & valuation, ONCO or ZVSA?

Does the media prefer ONCO or ZVSA?

Do institutionals & insiders believe in ONCO or ZVSA?

Which has more risk and volatility, ONCO or ZVSA?

Is ONCO or ZVSA more profitable?

Summary

How does ZyVersa Therapeutics compare to Genprex?

Which has more risk & volatility, GNPX or ZVSA?

Is GNPX or ZVSA more profitable?

Which has stronger earnings and valuation, GNPX or ZVSA?

Do analysts prefer GNPX or ZVSA?

Do insiders & institutionals have more ownership in GNPX or ZVSA?

Does the media prefer GNPX or ZVSA?

Summary

How does ZyVersa Therapeutics compare to BioXcel Therapeutics?

Which has more volatility and risk, ZVSA or BTAI?

Is ZVSA or BTAI more profitable?

Do analysts recommend ZVSA or BTAI?

Which has preferable earnings & valuation, ZVSA or BTAI?

Do insiders and institutionals believe in ZVSA or BTAI?

Does the media favor ZVSA or BTAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVSA vs. The Competition

ZyVersa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools